XML 54 R38.htm IDEA: XBRL DOCUMENT v3.22.2
REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue recognition $ 73,855 $ 48,625 $ 138,332 $ 103,146
Sales of generic pharmaceutical products        
Revenue recognition 49,863 34,199 98,970 66,812
Sales of established brand pharmaceutical products        
Revenue recognition 8,463 11,038 16,915 18,555
Sales of rare disease pharmaceutical products        
Revenue recognition 10,202   11,494  
Sales of contract manufactured products        
Revenue recognition 4,389 2,322 7,293 4,895
Royalties from licensing agreements        
Revenue recognition 194   2,097 11,210
Product development services        
Revenue recognition 531 97 1,097 255
Other        
Revenue recognition $ 213 $ 969 $ 466 $ 1,419